Stay updated on Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial page.

Latest updates to the Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial page
- Check7 days agoChange DetectedResults posted for NCT03007732 on 2025-12-05, with updated Cohort 2 endpoints and expanded safety and efficacy descriptions. The update also includes links to the study protocol and statistical analysis plan.SummaryDifference3%

- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedThe page revision was updated to v3.3.2 and v3.2.0 was removed, with no changes to substantive study details. The update affects only the page version metadata. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check28 days agoChange DetectedResults Submitted is now listed as a status on the page. The previous No Results Posted notice has been removed, indicating a change in the results availability status.SummaryDifference0.4%

- Check42 days agoChange DetectedAdministrative update to the study record reflecting a new last update date; no changes to the interventions, eligibility criteria, primary or secondary outcomes, or locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check71 days agoChange DetectedMajor update: announces a version upgrade to v3.2.0 and publicly states funding-related operational notices, including that transactions may not be processed until appropriations are enacted.SummaryDifference2%

- Check78 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial page.